


OVERVIEW


- Privately held clinical-stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders
- Decades of scientific leadership in engineering proprietary therapies to non-invasively penetrate the blood brain barrier
- Eight compounds in development for the treatment of currently unaddressed neurological complications of lysosomal storage disorders; establishing partnerships to address the unmet need in neurodegenerative diseases
- Lead therapies in early-stage clinical trials
 - AGT-182 for Hunter syndrome (MPS II) in Phase 1 clinical trials
 - AGT-181 for Hurler syndrome (MPS I) in a Phase 2 proof-of-concept trial

BUSINESS MODEL

- Advancing an innovative pipeline through licensing and collaboration agreements, in-house development programs and future partnering opportunities

PIPELINE

PRODUCT	PROPOSED INDICATION	DISCOVERY	PRECLINICAL	PRE-IND	PHASE 1	PHASE 2	PARTNER
AGT-181	Hurler syndrome (MPS I)						
AGT-182	Hunter syndrome (MPS II)						
AGT-183	Metachromatic leukodystrophy						
AGT-184	Sanfilippo A						

PRODUCT	PROPOSED INDICATION	DISCOVERY	PRECLINICAL	PRE-IND	PHASE 1	PHASE 2	PARTNER
AGT-115	Parkinson's, stroke						
AGT-190	Parkinson's, stroke						
AGT-110	Parkinson's, ALS, Alzheimer's, stroke						
AGT-160	Alzheimer's						
N/A	Neuroscience						

SOLVING THE BLOOD-BRAIN BARRIER DILEMMA

- ArmaGen's approach takes advantage of the body's natural system to non-invasively deliver drugs across the BBB
- The BBB selectively allows vital nutrients to pass from the bloodstream to the brain, through the presence of receptors that enable the entry of compounds such as insulin and transferrin (protein that transports iron)
- ArmaGen's technology platform targets the same receptors that transport these compounds to the brain. Scientists fuse the therapeutic to an antibody that binds to this specific receptor, enabling the fusion protein to travel through the BBB

HEADQUARTERS

Calabasas, CA

INVESTORS

ArmaGen has raised over \$50M in equity, non-dilutive SBIR awards and its licensing arrangement for AGT-182 with Shire.

ArmaGen closed a \$17 million series A financing in 2012 led by a consortium of top biopharmaceutical investment firms:



MITSUI GLOBAL INVESTMENT

MANAGEMENT



Mathias Schmidt, Ph.D.
Chief Executive Officer



William M. Partridge, M.D.
Founder and
Chief Scientific Officer



Ruben Boado, Ph.D.
Co-founder and
Vice President of Research
and Development



Patrice Rioux, M.D., Ph.D.
Senior Vice President of
Global Clinical Development



Sheri Barrack, Ph.D.
Vice President of
Pharmaceutical Development



Douglas Hunt, FRAPS
Vice President of Regulatory
Affairs and Quality Assurance



Derek Kelaita, MBA
Vice President of
Business Development

PLEASE VISIT ARMAGEN.COM FOR MORE INFORMATION



Engineering Biotechnology for the Brain